1
|
Tayama T, Okada H, Ogawa K, Marsteller D, Maeda H, Hruska MW, Kagawa Y. Population Pharmacokinetics of the Novel Adenosine A 2A Antagonist/Inverse Agonist KW-6356 and Its Active Metabolite Following Single and Multiple Oral Administration in Healthy Individuals and Patients with Parkinson's Disease. Clin Pharmacol Drug Dev 2024; 13:549-559. [PMID: 38178727 DOI: 10.1002/cpdd.1359] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/07/2023] [Accepted: 11/28/2023] [Indexed: 01/06/2024]
Abstract
KW-6356 is a selective antagonist and inverse agonist of the adenosine A2A receptor. The primary aim of the present analysis was to characterize the pharmacokinetics (PK) of KW-6356 and its active metabolite M6 in healthy subjects and patients with Parkinson's disease (PD). We pooled concentration-time data from healthy subjects and patients with PD who were administered KW-6356. Using these data, we developed a population PK model by sequentially fitting the KW-6356 parameters followed by the M6 parameters. A first-order absorption with a 1-compartment model for KW-6356 and a 1-compartment model for M6 best described the profiles. The covariates included in the final models were food status (fed/fasted/unknown) on first-order absorption rate constant, baseline serum albumin level on apparent clearance of KW-6356, and baseline body weight on apparent volume of distribution of KW-6356 and apparent clearance of M6. No covariate had a clinically meaningful impact on KW-6356 or M6 exposure.
Collapse
Affiliation(s)
- Tomonori Tayama
- Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan
- Laboratory of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
| | - Hiroki Okada
- Clinical Pharmacology, Kyowa Kirin, Inc., Princeton, NJ, USA
| | - Kotoko Ogawa
- Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan
| | | | - Hiroshi Maeda
- Clinical Pharmacology, Kyowa Kirin Co., Ltd, Tokyo, Japan
| | | | - Yoshiyuki Kagawa
- Laboratory of Clinical Pharmaceutics, School of Pharmaceutical Sciences, University of Shizuoka, Shizuoka, Japan
| |
Collapse
|
2
|
Ko IG, Jin JJ, Hwang L, Kim SH, Kim CJ, Han JH, Lee S, Kim HI, Shin HP, Jeon JW. Polydeoxyribonucleotide Exerts Protective Effect Against CCl 4-Induced Acute Liver Injury Through Inactivation of NF-κB/MAPK Signaling Pathway in Mice. Int J Mol Sci 2020; 21:ijms21217894. [PMID: 33114315 PMCID: PMC7660684 DOI: 10.3390/ijms21217894] [Citation(s) in RCA: 14] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/28/2020] [Revised: 10/19/2020] [Accepted: 10/22/2020] [Indexed: 02/06/2023] Open
Abstract
Acute liver injury (ALI) causes life-threatening clinical problem, and its underlying etiology includes inflammation and apoptosis. An adenosine A2A receptor agonist, polydeoxyribonucleotide (PDRN), exhibits anti-inflammatory and anti-apoptotic effects by inhibiting the secretion of pro-inflammatory cytokines. In the current study, the protective effect of PDRN against carbon tetrachloride (CCl4)-induced ALI was investigated using mice. For the induction of ALI, mice received intraperitoneal injection of CCl4 twice over seven days. Mice from the PDRN-treated groups received an intraperitoneal injection of 200 μL saline containing PDRN (8 mg/kg), once a day for seven days, starting on day 1 after the first CCl4 injection. In order to confirm that the action of PDRN occurs through the adenosine A2A receptor, 8 mg/kg 3,7-dimethyl-1-propargylxanthine (DMPX), an adenosine A2A receptor antagonist, was treated with PDRN. Administration of CCl4 impaired liver tissue and increased the liver index and histopathologic score. The expression of pro-inflammatory cytokines was increased, and apoptosis was induced by the administration of CCl4. Administration of CCl4 activated nuclear factor-kappa B (NF-κB) and facilitated phosphorylation of signaling factors in mitogen-activated protein kinase (MAPK). In contrast, PDRN treatment suppressed the secretion of pro-inflammatory cytokines and inhibited apoptosis. PDRN treatment inactivated NF-κB and suppressed phosphorylation of signaling factors in MAPK. As a result, liver index and histopathologic score were reduced by PDRN treatment. When PDRN was treated with DMPX, the anti-inflammatory and anti-apoptotic effect of PDRN disappeared. Therefore, PDRN can be used as an effective therapeutic agent for acute liver damage.
Collapse
Affiliation(s)
- Il-Gyu Ko
- Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea; (I.-G.K.); (J.-J.J.); (L.H.); (S.-H.K.); (C.-J.K.)
| | - Jun-Jang Jin
- Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea; (I.-G.K.); (J.-J.J.); (L.H.); (S.-H.K.); (C.-J.K.)
| | - Lakkyong Hwang
- Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea; (I.-G.K.); (J.-J.J.); (L.H.); (S.-H.K.); (C.-J.K.)
| | - Sang-Hoon Kim
- Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea; (I.-G.K.); (J.-J.J.); (L.H.); (S.-H.K.); (C.-J.K.)
| | - Chang-Ju Kim
- Department of Physiology, College of Medicine, Kyung Hee University, Seoul 02447, Korea; (I.-G.K.); (J.-J.J.); (L.H.); (S.-H.K.); (C.-J.K.)
| | - Jin Hee Han
- Department of Anesthesiology and Pain Medicine, College of Medicine, Kyung Hee University, Seoul 02447, Korea;
| | - Seunghwan Lee
- Department of Surgery, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea;
| | - Ha Il Kim
- Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea; (H.I.K.); (H.P.S.)
| | - Hyun Phil Shin
- Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea; (H.I.K.); (H.P.S.)
| | - Jung Won Jeon
- Department of Internal Medicine, Kyung Hee University Hospital at Gangdong, College of Medicine, Kyung Hee University, Seoul 05278, Korea; (H.I.K.); (H.P.S.)
- Correspondence: ; Tel.: +82-2-440-6280
| |
Collapse
|
3
|
Ramos-Font C, Jimenez-Heffernan A, González Jimenez A, Rashki M, Llamas Elvira JM. Regadenoson long-lasting use induced tachyarrythmia. J Nucl Cardiol 2019; 26:1036-1039. [PMID: 30565060 DOI: 10.1007/s12350-018-01561-3] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/18/2018] [Accepted: 10/01/2018] [Indexed: 10/27/2022]
Affiliation(s)
- Carlos Ramos-Font
- Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain.
| | | | - Antonio González Jimenez
- Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain
| | - Mahsa Rashki
- Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain
| | - Jose Manuel Llamas Elvira
- Nuclear Medicine Department, Hospital Universitario Virgen de las Nieves, Avd de las Fuerzas Armadas 2, Granada, Spain
| |
Collapse
|
4
|
Salgado-Garcia C, Jimenez-Heffernan A, Lopez-Martin J, Molina-Mora M, Aroui T, Sanchez de Mora E, Ramos-Font C, Rivera de Los Santos F, Ruiz-Frutos C. Influence of body mass index and type of low-level exercise on the side effect profile of regadenoson. Eur J Nucl Med Mol Imaging 2017; 44:1906-1914. [PMID: 28547175 DOI: 10.1007/s00259-017-3717-1] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/02/2017] [Accepted: 04/27/2017] [Indexed: 11/25/2022]
Abstract
PURPOSE Regadenoson, an A2A adenosine receptor pharmacologic stress agent for radionuclide myocardial perfusion imaging (MPI), is administered as a single, fixed dose. We studied the side effect profile of regadenoson combined with two types of low-level exercise, according to body mass index (BMI). METHODS Three hundred and fifty-six patients (46.1% men, mean age 67.7±10.7 years, range 31-90 years) underwent regadenoson stress testing combined with low-level exercise. Subjects were classified according to BMI as normal, overweight, or obese, and the type of low-level exercise performed as walking on the treadmill (TE group, n=190) or forcefully swinging legs while sitting (SS group, n=166). Patients' demographics, medical history, clinical symptoms during stress, changes in ECG, oxygen saturation (SatO2), systolic blood pressure (SBP), and heart rate (HR) were evaluated. RESULTS Groups were comparable (p=ns) with regard to cardiovascular risks factors. The incidence of side effects was similar across BMI (p=ns), although the TE patients showed improved profiles over those with SS exercise, with a significantly lower incidence of flushing, dizziness and nausea/gastrointestinal discomfort (12.9% vs. 28.4%; 19.9% vs. 33.4%; 11.4% vs. 19.2%, respectively; all p<0.05). Regarding the hemodynamic response, we did not observe significant changes in SBP and HR after regadenoson administration across BMI categories. Comparing the TE and SS groups, no significant changes were observed in SBP, but there was a higher increase in HR in the TE group (p<0.05). CONCLUSIONS Regadenoson in combination with low-level exercise is safe and well tolerated over a wide range of BMI, with TE exercise showing a better side effect profile than SS.
Collapse
Affiliation(s)
- Carlos Salgado-Garcia
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain.
| | - Amelia Jimenez-Heffernan
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | - Juana Lopez-Martin
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | - Manuela Molina-Mora
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | - Tarik Aroui
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | - Elena Sanchez de Mora
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | - Carlos Ramos-Font
- Department of Nuclear Medicine, Hospital Juan Ramon Jimenez. Complejo Hospitalario Universitario de Huelva, Ronda Norte, s/n, 21005, Huelva, Spain
| | | | - Carlos Ruiz-Frutos
- Department of Environmental and Public Health, University of Huelva, 21071, Huelva, Spain
| |
Collapse
|
5
|
Nathan DG, Field J, Lin G, Neuberg D, Majerus E, Onyekwere O, Keefer J, Okam M, Ross A, Linden J. Sickle cell disease (SCD), iNKT cells, and regadenoson infusion. Trans Am Clin Climatol Assoc 2012; 123:312-318. [PMID: 23303999 PMCID: PMC3540605] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 06/01/2023]
Abstract
A humanized murine sickle cell-disease (SCD) model (NY1DD) has been used to study ischemia/reperfusion injury (IRI) in sickle cell anemia, and iNKT cells (a very small subset of murine and human T cells) have been found to instigate such injury in this model. Furthermore, levels of activated iNKT cells are generally elevated in the circulation of patients with SCD. Because activated iNKT cells are rich in adenosine A2A receptors which, when agonized, down-regulate the inflammatory cytokine expression that characterizes the cells, we have conducted a phase 1 trial of a constant infusion of low-dose regadenoson (an adenosine analogue with high A2A receptor specificity) to determine its safety and the capacity of a safe dose to down-regulate circulating iNKT cells in patients with SCD. We have found two dose rates that are both safe and effective and now plan a controlled Phase 2B clinical trial to determine whether our highest dose, administered as a 48-hour constant infusion, will induce faster remission in both painful vaso-occlusive crisis (pVOC) and acute chest syndrome (ACS).
Collapse
|